CNBC’s Jim Cramer on Tuesday told investors the market has breadth, with many winners other than the tech mega caps. He reviewed
Tag: Eli Lilly and Co
Watch for potential wave of share splits as the average price of S&P 500 stock hits $160, says Strategas
The market may see a new wave of stock splits, creating another growth catalyst for a market that wants to keep rallying,
Amgen aims to enter weight loss drug market with a new approach
The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California. Mario Tama | Getty Images Amgen
How much people are willing to spend
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters
New funds target weight loss, Big Tech hype: Roundhill Investments
A major exchange-traded fund provider is going deep on two popular plays: megacap tech and weight loss drug stocks. In health care,
Here’s who could be next to split their stock after Chipotle
Investors are watching for which company could be next after Chipotle announced Tuesday it will split its stock 50-shares-for-1 in June. Shares
Jim Cramer shares his thoughts on TSLA, HTZ, PEP, SMCI and VRT
Jim Cramer’s daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Tesla : Shares rose 5%
Wegovy heart health approval won’t mean broad insurance coverage yet
Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a
WeightWatchers CEO just sent a memo to employees as stock crashes
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to
FDA approves NASH liver disease drug from Madrigal Pharmaceuticals
In this photo illustration, the Madrigal Pharmaceuticals logo is displayed on a smartphone screen. Rafael Henrique | SOPA Images | Lightrocket |
No More Posts Available.
No more pages to load.